In a clinical study, multiple dosing of a GPR119 agonist JNJ-38431055 in subjects with T2D increased plasma GLP-1 and GIP levels, but this did not translate into improvements in 24 h blood glucose control [253]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.